Home > Insider Trading > Filing (0001209191-19-013905)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1636651	Ovid Therapeutics Inc.	OVID	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1256153	M Jeremy Levin	C/O Ovid Therapeutics Inc. 1460 Broadway, Suite 15044 New York NY 10036	Ceo	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-02-22	75,000	$2.00	4,676,529	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Acquisiton	2019-02-24	250,000	$0.00	250,000	$1.89

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
250,000		2029-02-23	No	4	A	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	35,461	Indirect	See Footnote
Common Stock	465,116	Indirect	See Footnote

Footnotes

The reportable securities are owned directly by Divo Holdings, LLC ("Divo"). The Reporting Person's spouse in the manager of Divo. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose.
The reportable securities are owned directly by DSL-EAL Holdings LLC (the "LLC"). The Reporting Person is the manager of the LLC. The Reporting Person may be deemed to share voting and investment powers for the shares held by the LLC. The Reporting Person disclaims beneficial ownership of the shares held by the LLC and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose, except to the extent of any pecuniary interest therein.
25% of the shares subject to the Stock Option will vest and become exercisable on February 24, 2020 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date.